RiaGev (Nicotinamide and D-Ribose)

RiaGev is a proprietary ingredient combining nicotinamide and D-ribose, designed to enhance cellular energy production. It primarily functions by boosting NAD+ levels, which are critical for metabolic processes and antioxidant defenses.

Origin & History

RiaGev is a multi-patented, proprietary branded combination of nicotinamide (a form of vitamin B3) and D-ribose (a pentose sugar), developed by Bioenergy Life Science for promoting cellular energy and healthy aging. It is produced through synthetic or commercial manufacturing of these compounds rather than extraction from natural sources, formulated into pharmaceutical-grade powder or supplement form.

Historical & Cultural Context

No historical or traditional medicinal use has been identified for RiaGev as a branded combination. Neither nicotinamide nor D-ribose have documented roles in traditional systems like Ayurveda, TCM, or other historical medicinal practices.

Health Benefits

• Increases NAD+ levels by 10.4% after 5 days (p=0.034) based on one small RCT (n=18)
• Elevates antioxidant glutathione and NADPH levels (19.1-27.6% increase over days 3-8, p≤0.008) in the same trial
• Improves energy and reduces fatigue scores by 12.7-21.5% vs. 4.1-10.4% placebo (p≤0.04) in healthy adults
• Lowers cortisol and blood glucose levels, improving insulin sensitivity without changing insulin levels (pilot trial evidence)
• Enhances subjective reports of sleep quality, mental concentration, and motivation in the crossover study

How It Works

RiaGev delivers a combination of nicotinamide and D-ribose, both essential precursors for nicotinamide adenine dinucleotide (NAD+) synthesis. Nicotinamide directly contributes to NAD+ salvage pathways, while D-ribose serves as a rate-limiting substrate in the de novo synthesis of purine and pyrimidine nucleotides, including NAD+. This synergistic delivery efficiently elevates intracellular NAD+ levels, crucial for ATP production via oxidative phosphorylation and the function of sirtuins and PARPs.

Scientific Research

Evidence comes from a single randomized, triple-blind, placebo-controlled, crossover pilot trial (NCT04483011, PMID: 35684021) in 18 healthy middle-aged adults (35-65 years), testing 1520 mg RiaGev twice daily for 8 days. No larger RCTs, meta-analyses, or long-term studies on RiaGev have been identified, limiting the strength of conclusions.

Clinical Summary

Clinical research on RiaGev, though limited to a small randomized controlled trial (n=18), indicates promising effects on cellular energy markers. Participants showed a 10.4% increase in NAD+ levels after just 5 days and significant elevations (19.1-27.6%) in antioxidant glutathione and NADPH. Furthermore, this trial reported a substantial improvement in energy and reduction in fatigue scores (12.7-21.5% vs. 4.1-10.4% placebo), suggesting potential benefits for energy support.

Nutritional Profile

RiaGev is a patented combination supplement containing two primary bioactive compounds: Nicotinamide (a form of vitamin B3/niacinamide) and D-Ribose (a naturally occurring pentose sugar). Typical serving provides approximately 200-300 mg of nicotinamide and 300-500 mg of D-Ribose per dose (exact proprietary ratios maintained by Bioenergy Life Science). Nicotinamide serves as a direct precursor to nicotinamide adenine dinucleotide (NAD+), entering the salvage pathway via nicotinamide phosphoribosyltransferase (NAMPT). D-Ribose is a five-carbon monosaccharide that serves as a substrate for the pentose phosphate pathway and contributes to the synthesis of the adenine dinucleotide backbone, NADPH, and ATP. Together, the two compounds synergistically support NAD+ biosynthesis — D-Ribose provides the ribose moiety required for the nicotinamide mononucleotide (NMN) intermediate, potentially enhancing flux through the salvage pathway beyond what nicotinamide alone achieves. Caloric contribution is negligible (<5 kcal per serving). Contains no significant macronutrients (fat, fiber, or protein), no minerals, and no additional vitamins beyond the B3 component. Bioavailability: Nicotinamide is highly bioavailable orally (near 100% absorption in the GI tract) with rapid conversion to NAD+ in the liver and peripheral tissues. D-Ribose is absorbed in the small intestine and has moderate oral bioavailability (~approximately 88% in human studies), bypassing the rate-limiting oxidative steps of the pentose phosphate pathway. The combination has been shown to elevate whole-blood NAD+ by 10.4% within 5 days, NADPH by 19.1-27.6% over days 3-8, and reduced glutathione (GSH) levels concurrently, indicating meaningful systemic bioactivity at supplemental doses. No known significant drug-nutrient interactions at standard doses, though high-dose nicotinamide may compete with methylation pathways (SAMe/methyl donor depletion at very high intakes). Free of common allergens, gluten, and artificial additives in most commercial formulations.

Preparation & Dosage

Clinically studied dosage: 1520 mg RiaGev powder twice daily (total 3040 mg/day). No other forms or dosage ranges have been tested in humans. The exact ratio of nicotinamide to D-ribose in the proprietary blend is not disclosed. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

NMN, Resveratrol, CoQ10, Alpha-Lipoic Acid, PQQ

Safety & Interactions

RiaGev, containing nicotinamide and D-ribose, is generally well-tolerated at recommended doses. Mild gastrointestinal upset has been reported with D-ribose, while high doses of nicotinamide can cause flushing, though the nicotinamide form in RiaGev is less likely to induce this. Individuals on blood sugar-lowering medications should monitor glucose levels due to D-ribose's potential impact. Pregnant or nursing individuals and those with pre-existing medical conditions should consult a healthcare professional before use.